Abstract:Background: Betaine is a methyl donor and has been considered as a lipotropic effect substance. But its mechanism remains unclear. Hepatic steatosis is associated with abnormal expression of genes involved in hepatic lipid metabolism. DNA methylation contributes to the disregulation of gene expression. Here we hypothesized that betaine supplement and subsequent DNA methylation modifications alter the expression of genes that are involved in hepatic lipid metabolism and hence alleviate hepatic triglyceride accumulation.Methods: Male wild-type (WT) C57BL/6 mice (n = 6) were fed with the AIN-93 G diet. ApoE(-/-) mice (n = 12), weight-matched with the WT mice, were divided into two groups (n = 6 per group), and fed with the AIN-93 G diet and AIN-93 G supplemented with 2% betaine/100 g diet. Seven weeks after the intervention, mice were sacrificed. Liver betaine, choline, homocysteine concentration were measured by HPLC. Liver oxidants activity and triglyceride level were assessed by ultraviolet spectrophotometry. Finally, hepatic PPAR alpha gene and its target genes expression levels and the methylation status of the PPAR alpha gene were determined.Results: ApoE(-/-) mice had higher hepatic triglyceride and lower GSH-Px activity when compared with the WT mice. Betaine intervention reversed triglyceride deposit, enhanced SOD and GSH-Px activity in the liver. Interestingly, mice fed on betaine-supplemented diet showed a dramatic increase of hepatic choline concentration and a decrease of betaine and homocysteine concentration relative to the WT mice and the ApoE(-/-) mice absent with betaine intervention. Expression of PPAR alpha and CPT1 were decreased and expression of FAS was markedly increased in ApoE(-/-) mice. In parallel, PPAR alpha promoter methylation level were slightly increased in ApoE(-/-) mice though without significance. Betaine supplement upregulated expression of PPAR alpha and its target genes (CPT1, CYP2E1) and reversed hypermethylation of PPAR alpha promoter of ApoE(-/-) mice. Furthermore, PPAR alpha methylation was positively correlated with hepatic betaine concentration.Conclusions: Our findings indicate that betaine supplement could alleviate hepatic triglyceride accumulation and improve antioxidant capacity by decreasing PPAR alpha promoter methylation and upregulating PPAR alpha and its target genes mRNA expression.

Berberine Reduces Methylation of the MTTP Promoter and Alleviates Fatty Liver Induced by a High-Fat Diet in Rats

Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet.

Demethylenetetrahydroberberine Alleviates Nonalcoholic Fatty Liver Disease by Inhibiting the NLRP3 Inflammasome and Oxidative Stress in Mice

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Berberine Reverses Abnormal Expression of L-type Pyruvate Kinase by DNA Demethylation and Histone Acetylation in the Livers of the Non-Alcoholic Fatty Disease Rat.

Fatty Liver Mediated by Peroxisome Proliferator‐activated Receptor‐α DNA Methylation Can Be Reversed by a Methylation Inhibitor and Curcumin

611-P: Berberine Prevented High-Fat Diet-Induced Metabolic Disorders via Inhibition of Whole Lipid Metabolism

Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice

Epigenetic Regulation of Hepatic Lipid Metabolism by DNA Methylation

Demethyleneberberine Attenuates Free Fatty Acid- And High Fat Diet-Induced Hepatic Lipotoxicity By Activating AMP-Activated Protein Kinase

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation

Demethyleneberberine Attenuates Non-Alcoholic Fatty Liver Disease with Activation of AMPK and Inhibition of Oxidative Stress.

Berberine Attenuates Hepatic Steatosis and Enhances Energy Expenditure in Mice by Inducing Autophagy and Fibroblast Growth Factor 21

Metabolomics Profiling to Investigate the Pharmacologic Mechanisms of Berberine for the Treatment of High-Fat Diet-Induced Nonalcoholic Steatohepatitis

Berberine Ameliorates Nonalcoholic Fatty Liver Disease by A Global Modulation of Hepatic Mrna and Lncrna Expression Profiles

Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

Betaine Supplement Alleviates Hepatic Triglyceride Accumulation of Apolipoprotein E Deficient Mice Via Reducing Methylation of Peroxisomal Proliferator-Activated Receptor Alpha Promoter

[Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet].

TET1 Promotes Fatty Acid Oxidation and Inhibits NAFLD Progression by Hydroxymethylation of PPARα Promoter

Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.

Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis